New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 4, 2014
20:25 EDTCOCO, COCO, NS, NS, LII, LII, BIP, BIP, NDAQ, NDAQ, LVLT, LVLT, GRA, GRA, CCE, CCE, BEAM, BEAM, RL, RL, MMP, MMP, HUM, HUM, EL, EL, CTSH, CTSH, AGN, AGN, ADP, ADP, TWX, TWX, MRK, MRKNotable companies reporting before tomorrow's open
Notable companies reporting before tomorrow's market open, with earnings consensus, include Merck (MRK), consensus 88c; Time Warner (TWX), consensus $1.15; Automatic Data Processing (ADP), consensus 77c; Allergan (AGN), consensus $1.34; Cognizant (CTSH), consensus $1.06; Estee Lauder (EL), consensus $1.06; Humana (HUM), consensus 94c; Magellan Midstream (MMP), consensus 81c; Ralph Lauren (RL), consensus $2.51; Beam (BEAM), consensus 72c; Coca-Cola Enterprises (CCE), consensus 52c; W.R. Grace (GRA), consensus $1.19; Level 3 (LVLT), consensus 3c; Nasdaq (NDAQ), consensus 67c; Brookfield Infrastructure Partners (BIP), consensus 35c; Lazard (LAZ), consensus 61c; Arrow Electronics(ARW), consensus $1.62; Lennox International (LII), consensus 74c; NuStar Energy (NS), consensus 35c; Corinthian Colleges (COCO), consensus 2c.
News For MRK;TWX;ADP;AGN;CTSH;EL;HUM;MMP;RL;BEAM;CCE;GRA;LVLT;NDAQ;BIP;LII;NS;COCO From The Last 14 Days
Check below for free stories on MRK;TWX;ADP;AGN;CTSH;EL;HUM;MMP;RL;BEAM;CCE;GRA;LVLT;NDAQ;BIP;LII;NS;COCO the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | all recent news | >>
April 11, 2014
18:44 EDTAGNJ&J halting development of Botox competitor, WSJ says
Subscribe for More Information
05:22 EDTMRKMerck says Hepatitis C combination therapy shows antiviral activity
Subscribe for More Information
April 10, 2014
17:44 EDTMRKMerck stock could return 20%, Barron's says
Subscribe for More Information
13:43 EDTNDAQFidelity to pitch new lost cost trading venue to large asset managers, WSJ says
Fidelity is working on a new trading venue, dubbed "Sakura," that it hopes will be a collaboration among big mutual-fund firms to reduce costs and streamline trading and will be an improvement over other "dark pools," reported The Wall Street Journal, citing people with knowledge of the matter. The report said Fidelity is in the initial planning stages and has just started pitching the idea to other large asset managers. Publicly traded fund managers include BlackRock (BLK), Franklin Resources (BEN) and T. Rowe Price (TROW), while Investment Technology Group (ITG) currently operates dark pools that facilitate block trading among large institutions. Exchange operators Nasdaq (NDAQ) and Intercontinentalexchange's (ICE) NYSE have previously testified to legislators that too much trading occurs in dark pools, hurting investors. Reference Link
11:35 EDTTWXCNN to use 9pm for original series, documentaries, Variety reports
Subscribe for More Information
10:47 EDTADP High option volume stocks: KOG PIP IPXL ADP EWH
Subscribe for More Information
10:14 EDTADPADP spin-off a positive development, says Wells Fargo
Subscribe for More Information
09:37 EDTMRKActive equity options trading on open
Active equity options trading on open according to Track Data: SIRI RAD AAPL AMZN AA FB TSLA MRK CVX C
09:21 EDTMRKOn The Fly: Pre-market Movers
Subscribe for More Information
09:06 EDTNDAQSEC still struggling for data, slow to move on HFT, Bloomberg says
Subscribe for More Information
09:04 EDTADPADP announces plan for spin-off of Dealer Services business
ADP announced that the company's board has approved a plan to separate the Dealer Services business into an independent publicly traded company through a tax-free spin-off of 100% of Dealer Services to ADP shareholders. In conjunction with the spin-off ADP expects to receive in a tax-free manner at least $700M, which proceeds ADP plans to return to its shareholders through share repurchases after the spin-off is complete, depending on market conditions. Following the spin-off, ADP expects to maintain its current 48c quarterly cash dividend per share. Over the medium to long term, ADP intends to return to its pre-separation target dividend payout ratio of 55% to 60%, while keeping intact ADP's 39 year track record of annual increases in its quarterly cash dividend, subject to approval by ADP's board. The spin-off will be completed upon receipt of all required regulatory reviews and approvals. ADP expects to complete the separation in the early part of Q4.
08:03 EDTMRKXencor Merck receives milestone payment from Merck for using XmAb antibody
Xencor (XNCR) announced that the company has received a milestone payment from Merck (MRK), through a subsidiary, triggered by the initiation of a Phase 1 clinical trial for an undisclosed biologic drug candidate that uses Xencor's XmAb antibody engineering intellectual property. Under the terms of the agreement signed in June 2013, Xencor granted Merck a non-exclusive license to certain Xencor patents for use in an undisclosed product, as well as an option to license the same intellectual property for future products. Xencor received an upfront payment and continues to receive annual maintenance fees. Xencor is also eligible to receive milestone payments associated with the successful development of Merck product candidates, as well as royalties on sales of any potential products that may result from this agreement.
06:04 EDTELYahoo hires Bobbi Brown to be editor-in-chief of beauty site, Re/code reports
Yahoo (YHOO) has hired Bobbi Brown, the creator of Bobbi Brown Cosmetics (EL), to be the editor-in-chief of its beauty site, Re/code reports, noting that several of Yahoo's big advertisers -- L'Oreal (LRLCY), Procter & Gamble (PG) and Unilever (UN, UL) -- are competitive with Bobbi Brown Cosmetics. Reference Link
05:27 EDTMRKMerck announces data from C-WORTHy study
Merck announced additional data from the ongoing C-WORTHy study, a multi-arm Phase 2 clinical trial evaluating the efficacy and safety of a once-daily, all-oral regimen combining MK-5172, an investigational hepatitis C virus, or HCV, NS3/4A protease inhibitor, and MK-8742, an investigational HCV NS5A replication complex inhibitor, among patients with chronic HCV Genotype 1 infection, or GT1. In an interim analysis of treatment-na´ve, non-cirrhotic patients administered a 12-week regimen of MK-5172/MK-8742, with and without ribavirin, or RBV, a sustained viral response, or SVR, was observed in 98% of patients administered MK-5172/MK-8742 alone and 94% in those administered MK-5172/MK-8742 plus RBV.
April 9, 2014
11:43 EDTMRKGilead defended by analysts after recent pullback
Subscribe for More Information
10:16 EDTCTSHHigh option volume stocks: IMGN GTN RDA AXAS CTSH
10:06 EDTNDAQOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
07:23 EDTMRKEuropean Association for the Study of the Liver to hold annual meeting
Subscribe for More Information
07:09 EDTMRKReckitt Benckiser may be frontrunner for Merck unit, Bloomberg reports
Subscribe for More Information
06:16 EDTNDAQNASDAQ downgraded to Neutral from Buy at BofA/Merrill
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | 6 | 7 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use